Y. Najima

Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes

[Integration of novel anti-tumor agents and allogeneic hematopoietic stem cell transplantation].

The use of venetoclax-based regimens, FLT3 inhibitors, and IDH inhibitors has improved treatment outcomes by enabling the achievement of measurable residual disease (MRD)-negative remission, highlighting the importance of maintenance strategies using azacitidine and FLT3 inhibitors, as well as MRD-guided preemptive int...

[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].

A review of the current concepts of post-transplant maintenance therapy in AML/MDS discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.

Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21)

This case suggests that sequential low-dose GO followed by stepwise DLI may support durable remission when used as a post-transplant maintenance strategy in chemo-refractory AML with adverse cytogenetics, such as t(1;3)(p36.3;q21).